# An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

> **NCT01790217** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 52 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01790217
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01790217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01790217, "An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01790217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*